Investment
CanSense seek equity investment of up to £2MGBP/ JPY428M for expansion into global markets.
- Series A | Scale business
Clinical Director at CanSense Ltd
CanSense Ltd is a Wales-based med-tech company developing blood-based diagnostics for early cancer detection. Built on research from Swansea University, the company combines Raman spectroscopy and AI to analyse biological signatures in standard blood samples, with an initial focus on bowel cancer and a broader platform for additional cancer indications. CanSense is advancing its technology through clinical validation, regulatory development, and strategic partnerships to deliver accessible, affordable, and scalable diagnostic solutions for the UK and global healthcare markets.
Business Domain / 分野
Business Type / 業種
Disease Area/疾患領域
Technologies / 技術
Additional Information
Requested business parter / ご希望のビジネスパートナー
Clinical Director
CanSense Ltd
Investment
CanSense seek equity investment of up to £2MGBP/ JPY428M for expansion into global markets.
Clinical Director at CanSense Ltd
Service
Colorectal cancer diagnostic testing
CanSense-CRC vaildated blood test for accurate and cost effective detection of spectral signatures of colorectal cancer and high-risk adenomas in blood serum.
Clinical Director at CanSense Ltd
Project cooperation
Clinical trial sites for clinical performance Study in colorectal cancer
We seek healthcare facilities and colonoscopy provider sites to support clinical trial recruitment towards CanSense PMDA approvals.
Clinical Director at CanSense Ltd
Service
Raman spectroscopy liquid testing solution for impurity detection and QA release contracting.
Clinical Director at CanSense Ltd